SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness

Abstract Background Additional epidermal growth factor receptor (EGFR) mutations confer the drug resistance to generations of EGFR targeted tyrosine kinase inhibitor (EGFR-TKI), posing a major challenge to developing effective treatment of lung adenocarcinoma (LUAD). The strategy of combining EGFR-T...

Full description

Bibliographic Details
Main Authors: Leiming Xia, Fan Yang, Xiao Wu, Suzhi Li, Chen Kan, Hong Zheng, Siying Wang
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Cancer Cell International
Subjects:
SHP2
T790M mutation
Lung adenocarcinoma
CXCL8 feedback loop
Stemness
Osimertinib
Online Access:https://doi.org/10.1186/s12935-021-02056-x

Similar Items

Similar Items